WHAT IS KNOWN AND OBJECTIVE: Pulmonary sarcomatoid carcinoma (PSC) is 
characterized by dismal prognosis and resistance to platinum-based chemotherapy. 
The immune checkpoint inhibitors showed promising efficacy in the treatment of 
PSC. Camrelizumab is a programmed cell death protein 1 inhibitor; however, 
current evidence of its efficacy in PSC is lacking.
CASE SUMMARY: A 47-year-old female non-smoker presented with central-type masses 
in the right upper and lower lobes. PSC (cT4N2M0, stage IIIB) with positive 
expression of programmed death ligand-1 was diagnosed. First-line camrelizumab 
plus doxorubicin and cisplatin was introduced, followed by camrelizumab 
monotherapy due to grade 4 leukopenia and thrombocytopenia during the 
combination therapy. The lesions indicated a partial remission which endured for 
more than 20 months.
WHAT IS NEW AND CONCLUSION: Camrelizumab plus doxorubicin and cisplatin regimen 
is a promising option for PSC patients. Further high-quality trials are 
warranted.